HHE Pathology and diagnostics supplement 2018 - Page 6

Table 1 Overview of analysis and reporting results in different subschemes of the 2016 ESP Lung EQA scheme Subscheme EGFR ALK FISH + digital ALK IHC ALK IHC technical evaluation Number of participants 97 113 102 90 Number of countries 28 26 31 30 Number of cases 10 9* 5 5 evaluated 95.0%* 95.0% 83.2% Average analysis score 92.0% (%) 71.1% 82.3%* 88.2% 94.4% Laboratories successful (%) 6.6% 0.7% 0.1% N/A Incorrectly genotyped samples (%) (64/970) (7/1017) (13/510) Laboratories with at 43.3% 6.2% 9.8% N/A least one incorrectly analyzed sample (%) 0.1% 2.2% 0.8% N/A Samples for which a technical failure (1/970) (22/1017) (4/510) occurred (%) 1.0% 12.4% 2.9% N/A Laboratories with at least one technical failure (%) 95 107 88 N/A Number of laboratories that submitted reports 86.1% 84.4% 84.0% N/A Average reporting score (%) 44.6% 43.0% 44.3% N/A Laboratories with the interpretation present and correct (%) N/A: not applicable. Written reports were not taken into account to determine successful participation on analysis level. For the technical evaluation, no written reports were scored. *9 cases were included to calculate the performance score instead of 10. The cut-off for successful participation was theref &RFVfVB2(SR7FVBb(SRf"F07V'66VRǒU&fFW0&&F&W2vFFR'GVGFfW&g@fƖFFRFV FW7BWFG2F"FV W&f&6R@6&RFFW &&F&W0v&GvFPF2W67&BvƖvG2FR&W7VG2bFPFW7B#bU66VRf"Tte"IJB$3Ǘ62442FFFǒ&V6VFF0&RFRgW'FW"&W6V&6VFRVFЦ6&RWfV2FB֖vB6G&'WFRF&fV@FW7FrVƗGWFG0FR&v6FbFRU5U66VW20W&f&VB6&&FvFFR6&FF6VG&R%&W6V&6VBbRWWfVv6267&VFFVB66&FrFFR4sC07FF&Bf"6f&֗G76W76VBb&f6V7FW7FrFR6WBWbV6U5VrU66VR2FWFW&֖VB&Vf&VB'7FVW&p6֗GFVRbFW&FWW'G2V7V Fv7F7266&FrFFRwVFVƖRFP&WV&VVG2bU&w&2V7V Fw&Vv7G&Fv2VF&&F&W0v&GvFR'F6G2&V6VfVBFVf&ƖЦfVB&ffV&VFFVBdeR6W2f"Tte f&BǗ62BffRdeR6W2f"İB$3&V'&vVVBFW7Frf"IJ@$3&&F&W26VB'F6FRfV&W66VB6GR&G&6Fd4@V7F6V֗7G'27V'66VRf d4ffRFFFFvF66W2vW&R&fFV@f"6vFW'&WFFǒf"2'F6G0vW&R6VBF6VB&6FV"7FVB6ƖFW2FFR6&FF6VG&RFWfVFRFPV7FrVƗG'FVbFW&FFv7G2FRFvFd4vW2vW&P`R#7FƆVF6&R6Цf&RfFvFFf&rvFFvF6VBVFƖBV67FVB6ƖFW0f"Fv7B&WfWr'F6G2vW&R6VBFǗ6RFR6W0W6rFV"&WFR&6VGW&W2F&VfV7B6Ɩ6&7F6RFRFVFƖRf"&W7VG27V&֗76v0B6VF"F2gFW"6R&V6VB66VP&W7VG2vW&RWfVFVB'FVbFW&F76W76'2f"V6FfGV7V'66VRw&VVVBvFFRUwVFVƖRWfW'6Rv2v&FVBGvG2f"6'&V7@&W7VBBG2vW&RFVGV7FVB66RbW'&"7V66W76gV'F6Ff"Tte"IJ@$3v2FVfVB266&Rb(SRbFRFF6Wf&R66&Rf"FRFV66WfVFbFRV7FrVƗG66&RffPG2v2v&FVBB7V66W76gVW72v0FVfVB266&Rb(S2RFRfW&vR&W'Fp66&Rv2FVfVB'FR66&rb6WfVFffW&VB66&R7&FW&f"f&BǗ62@2BR7&FW&f"d42FVfVB'FPwVFVƖR'F6G26VB7V&֗BFF@66W72FV"&W7VG2f77v&B&FV7FV@6VG&FF&6RFRU5VrU66VPvV'6FRGGVrW66VR&r&W7VG2bFR#b442U66VR&P6vF&R&W7VG2g&#.( 3#RU66VW2fR&WfW6ǒ&VVV&Ɨ6VBrÂFFVVR&&F&W2g&3B6VG&W0'F6FVB#bF'GR'F6G2g&Уb6VG&W2'F6FVBF&VR&W'0IJ$3BTte"fW&vRǗ6266&W2vW&R&fRRf